These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38443456)

  • 21. Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation.
    Amin NH; El-Saadi MT; Abdel-Fattah MM; Mohammed AA; Said EG
    Bioorg Chem; 2023 Jun; 135():106496. PubMed ID: 36989735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues.
    Ahsan MJ; Choupra A; Sharma RK; Jadav SS; Padmaja P; Hassan MZ; Al-Tamimi ABS; Geesi MH; Bakht MA
    Anticancer Agents Med Chem; 2018; 18(1):121-138. PubMed ID: 28425854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
    El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
    Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New 1,3,4-oxadiazoles linked with the 1,2,3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase.
    Mahmoud MA; Mohammed AF; Salem OIA; Gomaa HAM; Youssif BGM
    Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200009. PubMed ID: 35195309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
    A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
    Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
    Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
    Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors.
    Ibrahim TS; Malebari AM; Mohamed MFA
    Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
    Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
    Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
    Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
    Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.
    Ragab FA; Eissa AAM; Fahim SH; Salem MA; Gamal MA; Nissan YM
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100029. PubMed ID: 33872414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New benzimidazole based hybrids: Synthesis, molecular modeling study and anticancer evaluation as TopoII inhibitors.
    Nawareg NA; Mostafa AS; El-Messery SM; Nasr MNA
    Bioorg Chem; 2022 Oct; 127():106038. PubMed ID: 35870412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, Synthesis, and Antiproliferative Activity of Quinazolin-4-One/Chalcone Hybrids
    Hisham M; Hassan HA; Gomaa HAM; Youssif BGM; Hayalah AM; Abdel-Aziz M
    Anticancer Agents Med Chem; 2023; 23(17):1932-1943. PubMed ID: 37497685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iodoquinazoline-derived VEGFR-2 and EGFR
    Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
    Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents.
    Ahmed EA; Mohamed MFA; Omran OA
    RSC Adv; 2022 Sep; 12(39):25204-25216. PubMed ID: 36199335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study.
    Mansour NI; El-Sayed SM; El-Gohary NS; Abdel-Aziz NI; El-Subbagh HI; Ghaly MA
    Bioorg Chem; 2022 Oct; 127():105966. PubMed ID: 35728294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR
    Abo Al-Hamd MG; Tawfik HO; Abdullah O; Yamaguchi K; Sugiura M; Mehany ABM; El-Hamamsy MH; El-Moselhy TF
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241674. PubMed ID: 37548154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
    Alkamaly OM; Altwaijry N; Sabour R; Harras MF
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.